top of page

Eyes on Pharma
Check-out What Intel Caught our Eye


Recent M&A Activities
We're still tracking some of the ways firms are working to optimize their portfolios and managing competitive strategy. This week we're looking at two M&A deals: Ono Pharma's agreement with Biohaven for IgG degraders and Gilead's deal with Vir Bio for T-cell engagers. For the regional rights to three of Biohaven’s IgG degraders, including a phase 3-stage Grave’s disease potential, Japan’s Ono Pharmaceutical is paying $80 million up front. Ono also agreed to a $20 million mi

Jana Chisholm
Nov 95 min read


EyesOn The Competitive Edge
This week we're sharing a couple of articles focused on competitive advantage in US BioPharma. Take a look at how the Oral GLP-1 market is shaping up, and the new US Initiative Operation TrialBlazer is trying to boost US Early-Stage Clinical Development Capabilities.

Jana Chisholm
Jul 244 min read


EyesOn Strategic Agility
EyesOn Strategic Agility in Action: How Biopharma Companies Are Managing Clinical, Commercial, and Operational Levers to Sustain Growth

Jana Chisholm
Jun 217 min read
bottom of page
.png)